The Life Sciences team advised Gandeeva on its Series A funding led by Lux Capital and Leaps by Bayer, with participation from Obvious Ventures, Amgen Ventures, Amplitude Ventures and Air Street Capital.

Gandeeva is a precision biotechnology company harnessing the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop novel therapeutics at an accelerated pace.

The funding will be used to advance Gandeeva’s AI-driven cryo-EM platform with the aim to accelerate the discovery, design and development of novel precision medicines.

The Goodwin team included Michael Bison, Dan Hughes, and Cusaj Thomas (Corporate), Dan Karelitz (Tax), Brad Weber (Opinions), Alexandra DennistonRich Matheny and Gozde Guckaya (Global Trade), and Duncan Greenhalgh, Chris Denn, Jennifer Ford and Melissa Paddock (Intellectual Property).

For more details, read the press release.